C-Ray Therapeutics (Shanghai) Co Ltd, a Chinese developer of innovative targeted radiopharmaceuticals, said on Wednesday that during the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM 2025), it announced promising new clinical results for its lead programme 225Ac-PSMA-CY313 in the treatment of metastatic castration-resistant prostate cancer (mCRPC).

According to C-Ray, the data provide early clinical evidence of the therapy's significant potential and favourable safety profile, marking an important milestone for the company in the field of targeted alpha therapies. Both presentations were delivered by C-Ray's chief medical officer.

One presentation, entitled Feasibility study of 225Ac-PSMA-CY313 dosimetry in mCRPC patients using SPECT, showcased the company's progress in dosimetry research with 225Ac. The study successfully established and validated a quantitative dosimetry approach using SPECT/CT to evaluate internal radiation doses in patients treated with 225Ac-PSMA-CY313.

The second presentation, Evaluation of the safety and efficacy of 225Ac-PSMA-CY313 in metastatic castration-resistant prostate cancer: preliminary results, reported clinical outcomes from 13 patients treated with 225Ac-PSMA-CY313. The company says that the study results showed encouraging efficacy and manageable safety in heavily pretreated, standard therapy resistant mCRPC patients.